Yipinhong Pharmaceutical Co Ltd Class A (300723) — Tangible Net Worth Ratio
Yipinhong Pharmaceutical Co Ltd Class A (300723) has a Tangible Net Worth Ratio of 78.0% as of March 2026. This metric is calculated by deducting intangible assets (CN¥433.18 Million) from net assets (CN¥1.97 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See what is Yipinhong Pharmaceutical Co Ltd Class A's book value for net asset value and shareholders' equity analysis.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Yipinhong Pharmaceutical Co Ltd Class A Tangible Net Worth Ratio (2013–2025)
This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 78.0%, reflecting net assets of CN¥1.97 Billion with intangible assets of CN¥433.18 Million CNY. Also explore net asset momentum of Yipinhong Pharmaceutical Co Ltd Class A to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Yipinhong Pharmaceutical Co Ltd Class A (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For the full company profile including market capitalisation, see Yipinhong Pharmaceutical Co Ltd Class A market capitalisation.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 68.2% | CN¥1.41 Billion | CN¥447.63 Million | CN¥4.04 Billion | ▼ -9.0 pp |
| 2024 | 77.2% | CN¥1.94 Billion | CN¥441.17 Million | CN¥4.40 Billion | ▼ -5.6 pp |
| 2023 | 82.8% | CN¥2.60 Billion | CN¥446.79 Million | CN¥4.41 Billion | ▲ +4.1 pp |
| 2022 | 78.7% | CN¥2.17 Billion | CN¥460.97 Million | CN¥4.10 Billion | ▲ +1.5 pp |
| 2021 | 77.2% | CN¥2.02 Billion | CN¥460.42 Million | CN¥3.70 Billion | ▼ -2.9 pp |
| 2020 | 80.0% | CN¥1.50 Billion | CN¥298.34 Million | CN¥2.15 Billion | ▲ +3.4 pp |
| 2019 | 76.7% | CN¥1.34 Billion | CN¥312.91 Million | CN¥1.79 Billion | ▲ +3.5 pp |
| 2018 | 73.1% | CN¥1.30 Billion | CN¥349.33 Million | CN¥1.78 Billion | ▼ -12.5 pp |
| 2017 | 85.6% | CN¥1.11 Billion | CN¥159.69 Million | CN¥1.48 Billion | ▲ +36.7 pp |
| 2016 | 48.9% | CN¥336.50 Million | CN¥171.91 Million | CN¥752.32 Million | ▲ +31.3 pp |
| 2015 | 17.7% | CN¥200.66 Million | CN¥165.23 Million | CN¥630.56 Million | ▲ +39.2 pp |
| 2014 | -21.6% | CN¥127.52 Million | CN¥155.01 Million | CN¥733.80 Million | ▼ -72.5 pp |
| 2013 | 51.0% | CN¥185.61 Million | CN¥90.99 Million | CN¥411.27 Million | — |